443 related articles for article (PubMed ID: 9426870)
1. Parkinson's disease: drug therapy.
Oertel WH; Quinn NP
Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
Fischer PA
J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for early Parkinson's disease.
Stacy M; Brownlee HJ
Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
[TBL] [Abstract][Full Text] [Related]
4. [Initial treatment of Parkinson's disease].
Kulisevsky J; López-Villegas D
Rev Neurol; 1997 Aug; 25 Suppl 2():S163-9. PubMed ID: 9280684
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease therapy: treatment of early and late disease.
Jankovic J
Chin Med J (Engl); 2001 Mar; 114(3):227-34. PubMed ID: 11780303
[TBL] [Abstract][Full Text] [Related]
6. Other pharmacological treatments for motor complications and dyskinesias.
Waters C
Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy for Parkinson's disease.
Chen JJ; Swope DM
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
[TBL] [Abstract][Full Text] [Related]
8. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
10. [Current preclinical findings on substances against Parkinson's disease].
Gerlach M; Riederer P
Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease: managing symptoms and preserving function.
Sweeney PJ
Geriatrics; 1995 Sep; 50(9):24-31. PubMed ID: 7672615
[TBL] [Abstract][Full Text] [Related]
12. [Initiation of treatment in Parkinson disease].
Ghika J
Praxis (Bern 1994); 1995 Sep; 84(38):1018-20. PubMed ID: 7481298
[TBL] [Abstract][Full Text] [Related]
13. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Parkinson's disease.
Eadie MJ
Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
[TBL] [Abstract][Full Text] [Related]
15. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
Vaamonde J; Ibáñez R; Gudín M; Hernández A
Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
17. [Medicinal treatment of idiopathic Parkinson's disease].
Klockgether T
Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
[TBL] [Abstract][Full Text] [Related]
18. Moderate Parkinson's disease. Strategies for maximizing treatment.
Silverstein PM
Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
[TBL] [Abstract][Full Text] [Related]
19. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's disease: making the diagnosis, selecting drug therapies.
Scharre DW; Mahler ME
Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]